Event Type
Disclosure
Voluntary
Variant
8-K
Other Events MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induc